Prophylaxis against renal transplant rejection research hub

A Multicentre, Open-Label, Single Ascending Dose, Dose-Ranging, Phase I/IIa Study to Evaluate the Safety and Tolerability of an Autologous Antigen-Specific Chimeric Antigen Receptor T Regulatory Cell Therapy (TX200-TR101) in Living Donor Renal Transplant Recipients

This study is testing a new cell therapy (TX200-TR101) for kidney transplant patients. It aims to see if this treatment can help prevent the body from rejecting the new kidney and is safe to use. This is the first time this treatment is being given to people.